Ansofaxine

Mar 27, 2020

Luye Pharma Continues to Deliver Strong Growth in 2019

Mar 17, 2020

Major Depressive Disorder (MDD) Industry Assessment, 2017-2028 - Patient Population, Therapeutic Approaches, Pipeline Analysis, Market Size & Trends, Opportunities, Impact of Upcoming Therapies

Dec 26, 2019

Luye Pharma Submits New Drug Application in the U.S. for Its Antidepressant Drug LY03005

Aug 29, 2019

Luye Pharma First Half of 2019 Results: Strong Revenue Growth and Substantial Development of R&D Product Pipelines

May 30, 2019

Luye Pharma's Rykindo® NDA Filing Accepted by the U.S. FDA

Mar 28, 2019

Luye Pharma's Rykindo® Expected to Be the First Chinese Innovative Drug to Receive U.S. FDA Approval

Dec 30, 2018

Luye Pharma Announces Innovative Drug - Risperidone Extended Release Microspheres for Injection has Reached Final Stage of NDA Process

Aug 29, 2018

Luye Pharma Releases its Financial Results for the First Half of 2018: Double-Digit Growth in Core Product Sales, Exceeded Expectations in Sales, R&D and M&As

Jul 22, 2018

Luye Pharma Well Positioned for CNS Market with the Approval of A New Indication for Seroquel XR in China

Jun 25, 2018

Top 50 In Global Pharma By 2025 -- Luye Pharma Group Announces "Whole Value Chain" Global Collaboration Strategy

Jun 06, 2018

Seroquel Stepping Stone: How Luye Will Use Seroquel to Expand in Emerging Markets

May 27, 2018

Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR